Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351)
Open accessAbstract
The South African Medical Research Council, the Centers for Disease Control and Prevention, the ELMA South Africa Foundation, the Wellcome Trust, the Fogarty International Center of the National Institutes of Health, the FLAIR Fellowship program, the European and Developing Countries Clinical Trials Partnership 2 of the European Union Horizon 2020 program, the South African Research Chairs Initiative of the Department of Science and Innovation and the National Research Foundation.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Plasma from 22 persons infected with the Beta variant retained partial or full neutralizing activity against variants from earlier waves of the pandemic in all but three persons.
“Conversely, plasma from 22 persons infected with the Beta variant retained partial or full neutralizing activity against variants from earlier waves of the pandemic in all but three persons 101 .”
From The biological and clinical significance of emerging SARS-CoV-2 variants (2021) · cites this paper as [101]
The Beta variant has displayed 3-fold to 10-fold reduced susceptibility to 46% and >10-fold reduced susceptibility to 22% of convalescent plasma samples compared with early pandemic variants.
“The Beta variant has displayed 3-fold to 10-fold reduced susceptibility to 46% and >10-fold reduced susceptibility to 22% of convalescent plasma samples compared with early pandemic variants 97,101,104,121,124,203,204,[218][219][220] (fIg.5).”
From The biological and clinical significance of emerging SARS-CoV-2 variants (2021) · cites this paper as [101]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 5 · Cited by 128
- Authors
- Moyo-Gwete, T., Madzivhandila, M., Makhado, Z., Ayres, F., Mhlanga, D., Oosthuysen, B., Lambson, B. E., Kgagudi, P., Tegally, H., Iranzadeh, A., Doolabh, D., Tyers, L., Chinhoyi, L. R., Mennen, M., Skelem, S., Marais, G., Wibmer, C. K., Bhiman, J. N., Ueckermann, V., Rossouw, T., Boswell, M., de Oliveira, T., Williamson, C., Burgers, W. A., Ntusi, N., Morris, L., & Moore, P. L.
- Affiliations
- National Institute for Communicable Diseases (ZA)
- KwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South Africa
- University of Cape Town (ZA)
- Steve Biko Hospital (ZA)
- University of Pretoria (ZA)
- Corresponding author
- Moore, Penny L.
- ORCID
- Moyo-Gwete, Thandeka
- Makhado, Zanele
- Ayres, Frances
- Lambson, Bronwen E.
- Tegally, Houriiyah
- Iranzadeh, Arash
- Tyers, Lynn
- Mennen, Mathilda
- Marais, Gert
- Wibmer, Constantinos K.
- Bhiman, Jinal N.
- Ueckermann, Veronica
- Rossouw, Theresa
- Boswell, Michael
- Williamson, Carolyn
- Burgers, Wendy A.
- Ntusi, Ntobeko
- Morris, Lynn
- Moore, Penny L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-06-03
- Volume
- 384
- Issue
- 22
- Pages
- 2161-2163
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8063886
- OpenAlex
- W3149102402
- Cited by
- 128
- References
- 5
- Citations by year
- 2026: 1 · 2025: 7 · 2024: 8 · 2023: 16 · 2022: 43 · 2021: 53
- FWCI
- 9.47
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- UpSpace Institutional Repository (University of Pretoria) (submittedVersion)
- Funders
- South African Medical Research Council (96825)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 detection and testing
- Keywords
- SARS-CoV-2, B.1.351 variant, neutralizing antibodies, cross-reactivity, antibody response, COVID-19 pandemic, Omicron variant
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, Antibodies, Viral, Cross Reactions, Humans, Neutralization Tests, Antibodies, Neutralizing, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
